Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA...
-
Upload
david-stone -
Category
Documents
-
view
226 -
download
6
Transcript of Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA...
![Page 1: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/1.jpg)
Pseudocholinesterase Deficiency
Etiology and considerations
Angela HeplerRN, BS Biology, SRNA
Allegheny Valley Hospital School of Anesthesia
![Page 2: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/2.jpg)
Objectives
• 1. Review physiology, diagnosis, prevalence,
and effects of pseudocholinesterase deficiency
• 2. Address the management implications and
contraindications which result
• 3. Discuss alternative therapy choices
![Page 3: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/3.jpg)
Case Study
• 64 year old male undergoing craniotomy listing Succinylcholine as an “allergy”
• The patient has a diagnosis of pseudocholinesterase deficiency, secondary to a muscle biopsy
• H&P reveals hypertension, CAD, and hyperlipidemia
![Page 4: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/4.jpg)
Concerns
Craniotomies often involve:• Remifentanil, Propofol, and 0.5 MAC of volatile agent• Succinylcholine for induction, no long term paralytics• Antihypertensives on emergence, sometimes including
Esmolol
Succinylcholine is contraindicated, but can we still use Remifentanil and Esmolol?
![Page 5: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/5.jpg)
![Page 6: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/6.jpg)
![Page 7: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/7.jpg)
A&P Review• The Motor Neuron Body resides within the Grey Matter of
the spinal chord
• Axon terminates within the target muscle Myofibrils• Endplate• Neuromuscular Synapse
• Propagation of the impulse:• Releases Acetylcholine (Ach) into the synaptic cleft• Engages Nicotinicm receptors on the distal neuron
• Depolarizes and contracts the innervated muscle
![Page 8: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/8.jpg)
![Page 9: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/9.jpg)
![Page 10: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/10.jpg)
Motor end plate
Tb
Motor neuron
![Page 11: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/11.jpg)
![Page 12: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/12.jpg)
Succinylcholine• First used in 1951
• Chemically similar to 2 Acetylcholine (Ach) molecules
• Depolarizing neuromuscular blockade
• A competitive antagonist of Ach
• Short term paralysis, limited by pseudocholinesterase metabolism
![Page 13: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/13.jpg)
Acetylcholine and Succinylcholine
Acetylcholine Succinylcholine
![Page 14: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/14.jpg)
![Page 15: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/15.jpg)
Indications for Succinylcholine
• Rapid Sequence Induction (RSI)
• Electroshock Therapy (ECT)
• Motor evoked potential (MEP) monitoring
• Any situation where brief paralysis is desirable
![Page 16: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/16.jpg)
Pseudocholinesterase
• Also known as:
Acetylcholine Acyl Hydrolase
Butyrylcholinesterase (BChE)
• Primary metabolic pathway for Succinylcholine
• Located on Chromosome 3
![Page 17: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/17.jpg)
H
![Page 18: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/18.jpg)
,
![Page 19: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/19.jpg)
Pseudocholinesterase• Present in all tissues except RBCs
• Represents 0.01% of total body protein
• Results in Ester hydrolysis of:Succinylcholine, Mivacurium, Ester LA, Heroin, and Cocaine
• Unknown physiological use
![Page 20: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/20.jpg)
Pseudocholinesterase• Normal levels range from 3,000- 6,600 IU/L
• Lab testing is available for direct quantification
• Reportedly ≥ 80% of patients presenting with symptoms will have atypical pseudocholinesterase present
![Page 21: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/21.jpg)
Pseudocholinesterase inhibitors
• Onset of symptoms usually occurs when 75% suppression of the wild type is present
• Can occur with as little as 50% depression, depending on comorbidities and coexisting conditions
![Page 22: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/22.jpg)
Pseudocholinesterase inhibitors• Each can decrease the effectiveness of normal BChE:
• Advancing Age
• Renal failure
• Malnutrition
• Hepatic failure
• Pregnancy
![Page 23: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/23.jpg)
![Page 24: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/24.jpg)
HELLP -Induced Deficiency
• Case study:
• Primigravida at 29 wk gestation, presented with abdominal pain
• Day 1-2: medically managed, tocolytics administered
• Day 3: Rapid elevation in LFT’s and deterioration, decision made C-Section
![Page 25: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/25.jpg)
Departure from “the norm”…..
![Page 26: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/26.jpg)
HELLP-Induced Deficiency
• Case study (cont.):• Plt count 125,000/µL- Spinal and Epidural deferred
• GETA, intraoperatively stable, no long term paralysis• End of surgery: No response to TOF stimulus
• ICU, extubated 3 hours post section• Pseudocholinesterase levels ~ 2,200 IU/L
• Spontaneous return to normal levels as LFT’s returned to baseline on POD 16
![Page 27: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/27.jpg)
Other Cholinesterase inhibitors• Organophosphates- permanent
• Carbamates – temporary (our reversal agents)
• Various medications: some antidepressants, antibiotics, and chemotherapeutics
echothiophate, LAs, cocaine and heroin
• Malignancies
• Burns
• Cardiopulmonary Bypass
![Page 28: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/28.jpg)
Comorbidities with multifaceted deficiency
• Case Study:
• 54 year old female
• 5’4”, 156 kg
• OSA
• Recent prolonged exposure to pesticides
Presenting with Cellulitis of the Abdomen; for I&D
![Page 29: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/29.jpg)
![Page 30: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/30.jpg)
Comorbidities with multifaceted deficiency
• Case Study:
• No TOF response post Succinylcholine
• Remained intubated x 12 hours
• Post op Pseudocholinesterase level: 552 IU/L
• 6 months post: ~ 700 IU/L: Undiagnosed homozygous deficiency
![Page 31: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/31.jpg)
Atypical Pseudocholinesterase
• Results from a mutation of the BCHE gene
All atypical varieties are autosomal recessive:
• Heterozygous patients: minimal prolongation of paralysis• Homozygous: variable paralysis, from 1-4 hours or more
• More prevalent among:
• Inuit / Native Alaskans• Persian descendants/Jewish communities• Specific Hindu populations
![Page 32: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/32.jpg)
N
d
N- normal genetic coding (wild type allele)d- heterozygous, atypical BCHE (carrier) - homozygous, atypical BCHE
N d
NN Nd
Nd
N N
NN NN
Nd Nddd
The Genetics Of It All
![Page 33: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/33.jpg)
Pseudocholinesterase Variants
• Up to 98% of individuals are homozygous for normal pseudocholinesterase
• 4 major varieties, with 65 variants known
![Page 34: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/34.jpg)
![Page 35: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/35.jpg)
Pseudocholinesterase Deficiency types
1. K variant
• Minimal effects alone, but often present in conjunction with other variants
• Slight prolongation of apnea
• Most prevalent variant (1.5% population)
![Page 36: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/36.jpg)
Pseudocholinesterase Deficiency types
2. Dibucaine resistant/ Atypical
• First subtype identified
• Paralysis can last up to 2 hours
• Affects 0.01-0.03%
![Page 37: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/37.jpg)
Pseudocholinesterase Deficiency types• Dibucaine Number
• A qualitative test of enzyme activity
• Dibucaine (Nupercaine) attenuates normal enzyme action, but the atypical type is unaffected
• Normal: 80 (80% attenuation of BChE)
• Heterozygous: 40-60 (reduced attenuation)
• Homozygous: 20 or less (only slight attenuation noted)
![Page 38: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/38.jpg)
Pseudocholinesterase Deficiency types (cont.)
• 3. Silent variant
oHomozygous results in complete lack of pseudocholinesterase
oAll metabolism by alternative methods
oRelatively rare (0.008-0.01%)
oParalysis can last 3-4 hours
![Page 39: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/39.jpg)
Pseudocholinesterase Deficiency types (cont.)
• 4. Fluoride resistant
• Very rare (0.0007%)
• Effects similar to Dibucaine resistant variant
• Fluoride number
• Quantitative test, similar to Dibucaine number test
• Normal Fluoride number: 55-65
![Page 40: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/40.jpg)
Treatment…….
![Page 41: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/41.jpg)
Treatment• Supportive measures for unanticipated prolonged paralysis
• Known Congenital deficiency:• Avoid Succinylcholine with known congenital deficiency • Avoid Tetracaine, Chloroprocaine, and Procaine (OB patients)
• Consider NDMR in patients with potential for attenuated pseudocholinesterase activity
• ALWAYS assess for return of muscle function (TOF) prior to NDMR following Succinylcholine administration
![Page 42: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/42.jpg)
Alternative Therapies
• RSI and ECT- Consider low dose Rocuronium, Vecuronium or Cisatracurium
• MEP testing- consider Remifentanil for depressed respiratory effort (cough) and/or higher volatile agent concentrations
• Plant-derived recombinant pseudocholinesterase?
![Page 43: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/43.jpg)
What about our Case Study?
![Page 44: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/44.jpg)
What about our Case Study?
• Remifentanil- metabolized by nonspecific plasma esterases
• Esmolol- metabolized by RBC esterases
Both are unaffected by BChE deficiency
![Page 45: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/45.jpg)
What about our Case Study?
• Our plan of care:• Intubated with minimal Rocuronium dosage, with
spontaneous recovery during positioning
• Baseline MEP’s then obtained
• Remifentanil, Propofol, and 0.5 MAC
• Nitroglycerin, Hydralazine, and Labetalol used on emergence
• Patient awake within 5-7 minutes of Remifentanil termination, fully responsive with no respiratory depression
![Page 46: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/46.jpg)
Summary• Pseudocholinesterase (BChE) deficiency can be:
• 1. Drug, environment, or comorbidity induced (affecting quality)• 2. Congenital (affecting quantity of true BChE)
• Heterozygous carriers -slightly prolonged paralysis
• Homozygous silent type -most prolonged paralysis
• Alternative therapies include intermediate acting paralytics, volatile gases, and opioids
![Page 47: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/47.jpg)
Questions?
![Page 48: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/48.jpg)
References• Soliday, Conley, Henker. “Pseudocholinesterase deficiency: A Comprehensive
Review of Genetic, Acquired, and Drug Influences.” AANA Journal 2010: Vol. 78, No. 4, p313-320.
• http://stevegallik.org/sites/histologyolm.stevegallik.org/htm/HOLM_Chapter07_Page06.html
• Manullang, J., and T. D. Egan. "Remifentanil's effect is not prolonged in a patient with pseudocholinesterase deficiency." Anesthesia and analgesia 89.2 (1999): 529.
• Niazi, Ahtsham, Irene E. Leonard, and Breda O'Kelly. "Prolonged neuromuscular blockade as a result of malnutrition-induced pseudocholinesterase deficiency." Journal of clinical anesthesia 16.1 (2004): 40-42.
• Williams, Joseph, et al. "Pseudocholinesterase deficiency and electroconvulsive therapy." The journal of ECT 23.3 (2007): 198-200.
• Lang, John B., Susan A. Kunsman, and Michael T. Hartman. "Acquired pseudocholinesterase deficiency." Current Anaesthesia & Critical Care 21.5 (2010): 297-298.
![Page 49: Pseudocholinesterase Deficiency Etiology and considerations Angela Hepler RN, BS Biology, SRNA Allegheny Valley Hospital School of Anesthesia.](https://reader031.fdocuments.net/reader031/viewer/2022032307/56649cd65503460f9499d72e/html5/thumbnails/49.jpg)
References• Lurati, A. R. "Organophosphate exposure with pseudocholinesterase
deficiency." Workplace health & safety 61.6 (2013): 243-245• Geyer, Brian C., et al. "Reversal of Succinylcholine Induced Apnea with an
Organophosphate Scavenging Recombinant Butyrylcholinesterase." Plos one 8.3 (2013): e59159.
• Bryson, E. O., et al. "Prolonged succinylcholine action during electroconvulsive therapy (ECT) after cytarabine, vincristine, and rituximab chemotherapy." The journal of ECT 27.1 (2011): e42.
• Sivak, Erica L., and Peter J. Davis. "Review of the efficacy and safety of remifentanil for the prevention and treatment of pain during and after procedures and surgery." Local and regional anesthesia 3 (2010): 35.
• Cerf, C., Mesguish, M. et al. “Screening patients with prolonged neuromuscular blockade after Succinylcholine and Mivacurium.” Anesthesia & Analgesia 2002; 94:461-66.
• Lurie, Samuel, Sadan, Oscar, et al. “Pseudocholinesterase deficiency asociated with HELLP syndrome”. American Journal of Perinatology, 2004; 21:315-17.